CompletedNCT04466345
Semaglutide for Thinking Difficulties in Major Depression
About this title
Read the official source — NCT04466345Placebo comparisonAges 18–60Canada
Understand this study
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 60 years. Other eligibility criteria applied.
- Listed locations
- TorontoSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateStarted: October 6, 2021
- Recruitment status
- Completed
- Enrollment listed in the registry
- 72
- Sponsor
- University Health Network, Toronto
- Sponsor type
- University
- Study type
- Biological
- Intervention type
- Biological
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- Canada
- Age range
- From 18 Years to 60 Years
- Official registry ID
- NCT04466345
- Official title
Show the full official title
Adjunctive Semaglutide for the Treatment of Cognitive Dysfunction in Major Depressive Disorder: a Randomized, Double-Blind, Placebo-Controlled Study
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Toronto
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is University Health Network, Toronto, a university.
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 60 years. Other eligibility criteria applied.
